PKM and small cell lung carcinoma: Indeed, in the LS-SCLC group, shorter median PFS was observed in patients with high mRNA expression of ERCC1 (7.9 vs. 10.1 months; p = 0.028), PKM2 (7.1 vs. 9.0 months; p = 0.046), TOPOI (7.8 vs. 10.2 months; p = 0.008), TOPOIIA (7 vs. 9.3 months; p = 0.002) and TOPOIIB (6.6 vs. 9.1 months; p <0.001) in comparison with those with low expression of these genes (Table S4 and Figure 1).